Loading…
Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma
The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion,...
Saved in:
Published in: | The Journal of pathology 2018-03, Vol.244 (3), p.283-295 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33 |
---|---|
cites | cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33 |
container_end_page | 295 |
container_issue | 3 |
container_start_page | 283 |
container_title | The Journal of pathology |
container_volume | 244 |
creator | Kucia‐Tran, Justyna A Tulkki, Valtteri Scarpini, Cinzia G Smith, Stephen Wallberg, Maja Paez‐Ribes, Marta Araujo, Angela M Botthoff, Jan Feeney, Maria Hughes, Katherine Caffarel, Maria M Coleman, Nicholas |
description | The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/path.5010 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2001686182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2001686182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</originalsourceid><addsrcrecordid>eNp1kL9u2zAQh4miQeP8GfoCAYFOHeSQlEiLo2GkcQAXzeDMAkUeawaSKJNSUm8d8gB9xj5J6DgtkCHTAXfffYf7IfSZkiklhF32athMOaHkA5pQIkUmSyk-okmasSwv6OwYncR4TwiRkvNP6JhJRngu2AQ9zbvB_f39x3fax0ENrsPfsUq92psddt3G1W6IeNgA7oNPYKsa97NLBAZrQaeZt_jNdgAN_eAD9g8Q4FcfIEbnuyTDcTuq1o8Ra2garFXQrvOtOkNHVjURzl_rKbr7drVeLLPVj-ubxXyV6YIXJCtKy6wysyKXVjMuC1PqPFeKgzFGc8o0NayeWZB5zUqrTS2pnQkQXDAi6jw_RV8O3vTKdoQ4VPd-DF06WTFCqCgFLVmivh4oHXyMAWzVB9eqsKsoqfZ5V_u8q33eib14NY51C-Y_-S_gBFwegEfXwO59U3U7Xy9flM8NPI-n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2001686182</pqid></control><display><type>article</type><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</creator><creatorcontrib>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</creatorcontrib><description>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.5010</identifier><identifier>PMID: 29205362</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Activation ; Angiogenesis ; Animals ; Antineoplastic Agents, Immunological - pharmacology ; Autocrine Communication ; Autocrine signalling ; Blocking antibodies ; Cell Line, Tumor ; Cervical carcinoma ; Cervix ; Copy number ; Female ; Gene Expression Regulation, Neoplastic ; head and neck ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - immunology ; Head and Neck Neoplasms - metabolism ; Head and Neck Neoplasms - pathology ; Humans ; Janus Kinase 2 - genetics ; Janus Kinase 2 - metabolism ; Lung Neoplasms - drug therapy ; Lung Neoplasms - immunology ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Metastases ; Metastasis ; Mice, Inbred NOD ; Mice, SCID ; neutralizing antibodies ; Oncostatin M ; Oncostatin M - genetics ; Oncostatin M - metabolism ; oncostatin M receptor ; Oncostatin M Receptor beta Subunit - antagonists & inhibitors ; Oncostatin M Receptor beta Subunit - genetics ; Oncostatin M Receptor beta Subunit - immunology ; Oncostatin M Receptor beta Subunit - metabolism ; Phosphorylation ; Secretion ; Signal Transduction ; SOCS-3 protein ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - immunology ; Squamous Cell Carcinoma of Head and Neck - metabolism ; Squamous Cell Carcinoma of Head and Neck - pathology ; STAT3 ; Stat3 protein ; STAT3 Transcription Factor - genetics ; STAT3 Transcription Factor - metabolism ; Suppressor of Cytokine Signaling 3 Protein - genetics ; Suppressor of Cytokine Signaling 3 Protein - metabolism ; Up-Regulation ; Uterine Cervical Neoplasms - drug therapy ; Uterine Cervical Neoplasms - immunology ; Uterine Cervical Neoplasms - metabolism ; Uterine Cervical Neoplasms - pathology ; Xenograft Model Antitumor Assays</subject><ispartof>The Journal of pathology, 2018-03, Vol.244 (3), p.283-295</ispartof><rights>Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</rights><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</citedby><cites>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</cites><orcidid>0000-0002-3331-1249 ; 0000-0002-5374-739X ; 0000-0001-8784-7025 ; 0000-0003-4730-5197 ; 0000-0002-7442-6827 ; 0000-0001-7744-3238</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29205362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kucia‐Tran, Justyna A</creatorcontrib><creatorcontrib>Tulkki, Valtteri</creatorcontrib><creatorcontrib>Scarpini, Cinzia G</creatorcontrib><creatorcontrib>Smith, Stephen</creatorcontrib><creatorcontrib>Wallberg, Maja</creatorcontrib><creatorcontrib>Paez‐Ribes, Marta</creatorcontrib><creatorcontrib>Araujo, Angela M</creatorcontrib><creatorcontrib>Botthoff, Jan</creatorcontrib><creatorcontrib>Feeney, Maria</creatorcontrib><creatorcontrib>Hughes, Katherine</creatorcontrib><creatorcontrib>Caffarel, Maria M</creatorcontrib><creatorcontrib>Coleman, Nicholas</creatorcontrib><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><title>The Journal of pathology</title><addtitle>J Pathol</addtitle><description>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><subject>Activation</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antineoplastic Agents, Immunological - pharmacology</subject><subject>Autocrine Communication</subject><subject>Autocrine signalling</subject><subject>Blocking antibodies</subject><subject>Cell Line, Tumor</subject><subject>Cervical carcinoma</subject><subject>Cervix</subject><subject>Copy number</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>head and neck</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - immunology</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Humans</subject><subject>Janus Kinase 2 - genetics</subject><subject>Janus Kinase 2 - metabolism</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>neutralizing antibodies</subject><subject>Oncostatin M</subject><subject>Oncostatin M - genetics</subject><subject>Oncostatin M - metabolism</subject><subject>oncostatin M receptor</subject><subject>Oncostatin M Receptor beta Subunit - antagonists & inhibitors</subject><subject>Oncostatin M Receptor beta Subunit - genetics</subject><subject>Oncostatin M Receptor beta Subunit - immunology</subject><subject>Oncostatin M Receptor beta Subunit - metabolism</subject><subject>Phosphorylation</subject><subject>Secretion</subject><subject>Signal Transduction</subject><subject>SOCS-3 protein</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - immunology</subject><subject>Squamous Cell Carcinoma of Head and Neck - metabolism</subject><subject>Squamous Cell Carcinoma of Head and Neck - pathology</subject><subject>STAT3</subject><subject>Stat3 protein</subject><subject>STAT3 Transcription Factor - genetics</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>Suppressor of Cytokine Signaling 3 Protein - genetics</subject><subject>Suppressor of Cytokine Signaling 3 Protein - metabolism</subject><subject>Up-Regulation</subject><subject>Uterine Cervical Neoplasms - drug therapy</subject><subject>Uterine Cervical Neoplasms - immunology</subject><subject>Uterine Cervical Neoplasms - metabolism</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kL9u2zAQh4miQeP8GfoCAYFOHeSQlEiLo2GkcQAXzeDMAkUeawaSKJNSUm8d8gB9xj5J6DgtkCHTAXfffYf7IfSZkiklhF32athMOaHkA5pQIkUmSyk-okmasSwv6OwYncR4TwiRkvNP6JhJRngu2AQ9zbvB_f39x3fax0ENrsPfsUq92psddt3G1W6IeNgA7oNPYKsa97NLBAZrQaeZt_jNdgAN_eAD9g8Q4FcfIEbnuyTDcTuq1o8Ra2garFXQrvOtOkNHVjURzl_rKbr7drVeLLPVj-ubxXyV6YIXJCtKy6wysyKXVjMuC1PqPFeKgzFGc8o0NayeWZB5zUqrTS2pnQkQXDAi6jw_RV8O3vTKdoQ4VPd-DF06WTFCqCgFLVmivh4oHXyMAWzVB9eqsKsoqfZ5V_u8q33eib14NY51C-Y_-S_gBFwegEfXwO59U3U7Xy9flM8NPI-n</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Kucia‐Tran, Justyna A</creator><creator>Tulkki, Valtteri</creator><creator>Scarpini, Cinzia G</creator><creator>Smith, Stephen</creator><creator>Wallberg, Maja</creator><creator>Paez‐Ribes, Marta</creator><creator>Araujo, Angela M</creator><creator>Botthoff, Jan</creator><creator>Feeney, Maria</creator><creator>Hughes, Katherine</creator><creator>Caffarel, Maria M</creator><creator>Coleman, Nicholas</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-3331-1249</orcidid><orcidid>https://orcid.org/0000-0002-5374-739X</orcidid><orcidid>https://orcid.org/0000-0001-8784-7025</orcidid><orcidid>https://orcid.org/0000-0003-4730-5197</orcidid><orcidid>https://orcid.org/0000-0002-7442-6827</orcidid><orcidid>https://orcid.org/0000-0001-7744-3238</orcidid></search><sort><creationdate>201803</creationdate><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><author>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Activation</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antineoplastic Agents, Immunological - pharmacology</topic><topic>Autocrine Communication</topic><topic>Autocrine signalling</topic><topic>Blocking antibodies</topic><topic>Cell Line, Tumor</topic><topic>Cervical carcinoma</topic><topic>Cervix</topic><topic>Copy number</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>head and neck</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - immunology</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Humans</topic><topic>Janus Kinase 2 - genetics</topic><topic>Janus Kinase 2 - metabolism</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>neutralizing antibodies</topic><topic>Oncostatin M</topic><topic>Oncostatin M - genetics</topic><topic>Oncostatin M - metabolism</topic><topic>oncostatin M receptor</topic><topic>Oncostatin M Receptor beta Subunit - antagonists & inhibitors</topic><topic>Oncostatin M Receptor beta Subunit - genetics</topic><topic>Oncostatin M Receptor beta Subunit - immunology</topic><topic>Oncostatin M Receptor beta Subunit - metabolism</topic><topic>Phosphorylation</topic><topic>Secretion</topic><topic>Signal Transduction</topic><topic>SOCS-3 protein</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - immunology</topic><topic>Squamous Cell Carcinoma of Head and Neck - metabolism</topic><topic>Squamous Cell Carcinoma of Head and Neck - pathology</topic><topic>STAT3</topic><topic>Stat3 protein</topic><topic>STAT3 Transcription Factor - genetics</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>Suppressor of Cytokine Signaling 3 Protein - genetics</topic><topic>Suppressor of Cytokine Signaling 3 Protein - metabolism</topic><topic>Up-Regulation</topic><topic>Uterine Cervical Neoplasms - drug therapy</topic><topic>Uterine Cervical Neoplasms - immunology</topic><topic>Uterine Cervical Neoplasms - metabolism</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kucia‐Tran, Justyna A</creatorcontrib><creatorcontrib>Tulkki, Valtteri</creatorcontrib><creatorcontrib>Scarpini, Cinzia G</creatorcontrib><creatorcontrib>Smith, Stephen</creatorcontrib><creatorcontrib>Wallberg, Maja</creatorcontrib><creatorcontrib>Paez‐Ribes, Marta</creatorcontrib><creatorcontrib>Araujo, Angela M</creatorcontrib><creatorcontrib>Botthoff, Jan</creatorcontrib><creatorcontrib>Feeney, Maria</creatorcontrib><creatorcontrib>Hughes, Katherine</creatorcontrib><creatorcontrib>Caffarel, Maria M</creatorcontrib><creatorcontrib>Coleman, Nicholas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kucia‐Tran, Justyna A</au><au>Tulkki, Valtteri</au><au>Scarpini, Cinzia G</au><au>Smith, Stephen</au><au>Wallberg, Maja</au><au>Paez‐Ribes, Marta</au><au>Araujo, Angela M</au><au>Botthoff, Jan</au><au>Feeney, Maria</au><au>Hughes, Katherine</au><au>Caffarel, Maria M</au><au>Coleman, Nicholas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J Pathol</addtitle><date>2018-03</date><risdate>2018</risdate><volume>244</volume><issue>3</issue><spage>283</spage><epage>295</epage><pages>283-295</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><abstract>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>29205362</pmid><doi>10.1002/path.5010</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3331-1249</orcidid><orcidid>https://orcid.org/0000-0002-5374-739X</orcidid><orcidid>https://orcid.org/0000-0001-8784-7025</orcidid><orcidid>https://orcid.org/0000-0003-4730-5197</orcidid><orcidid>https://orcid.org/0000-0002-7442-6827</orcidid><orcidid>https://orcid.org/0000-0001-7744-3238</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3417 |
ispartof | The Journal of pathology, 2018-03, Vol.244 (3), p.283-295 |
issn | 0022-3417 1096-9896 |
language | eng |
recordid | cdi_proquest_journals_2001686182 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Activation Angiogenesis Animals Antineoplastic Agents, Immunological - pharmacology Autocrine Communication Autocrine signalling Blocking antibodies Cell Line, Tumor Cervical carcinoma Cervix Copy number Female Gene Expression Regulation, Neoplastic head and neck Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - immunology Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - pathology Humans Janus Kinase 2 - genetics Janus Kinase 2 - metabolism Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - metabolism Lung Neoplasms - pathology Metastases Metastasis Mice, Inbred NOD Mice, SCID neutralizing antibodies Oncostatin M Oncostatin M - genetics Oncostatin M - metabolism oncostatin M receptor Oncostatin M Receptor beta Subunit - antagonists & inhibitors Oncostatin M Receptor beta Subunit - genetics Oncostatin M Receptor beta Subunit - immunology Oncostatin M Receptor beta Subunit - metabolism Phosphorylation Secretion Signal Transduction SOCS-3 protein Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - immunology Squamous Cell Carcinoma of Head and Neck - metabolism Squamous Cell Carcinoma of Head and Neck - pathology STAT3 Stat3 protein STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism Suppressor of Cytokine Signaling 3 Protein - genetics Suppressor of Cytokine Signaling 3 Protein - metabolism Up-Regulation Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - immunology Uterine Cervical Neoplasms - metabolism Uterine Cervical Neoplasms - pathology Xenograft Model Antitumor Assays |
title | Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90oncostatin%20M%20antibody%20inhibits%20the%20pro%E2%80%90malignant%20effects%20of%20oncostatin%20M%20receptor%20overexpression%20in%20squamous%20cell%20carcinoma&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Kucia%E2%80%90Tran,%20Justyna%20A&rft.date=2018-03&rft.volume=244&rft.issue=3&rft.spage=283&rft.epage=295&rft.pages=283-295&rft.issn=0022-3417&rft.eissn=1096-9896&rft_id=info:doi/10.1002/path.5010&rft_dat=%3Cproquest_cross%3E2001686182%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2001686182&rft_id=info:pmid/29205362&rfr_iscdi=true |